欧美日韩精品无码专区,成年无码av片,成品漫画免登录去广告版,亚洲精品一区国产

Keryx Biopharmaceuticals  
專注于收購，開發(fā)和商業(yè)化的醫(yī)學(xué)治療腎臟疾病的重要醫(yī)藥產(chǎn)品。

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing ZerenexTM (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of ZerenexTM for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is headquartered in New York City.

Keryx Biopharmaceuticals is traded on the Nasdaq Stock Market under the symbol "KERX."